|Date||Date of Registration : Aug 08, 2011
Date of Revision : Aug 08, 2011
|Country / Area||Russian Federation|
|Proposal Category||8802 Bio-medicine and therapeutics (vaccines, biological products, bio-diagnostics / pharmaceuticals, gene-diagnostics / therapeutics )|
|Target Country / Area||JAPAN|
*Attention: JETRO shall not take any responsibility for the contents provided by users. Please take note of the fact that JETRO leaves the exactness and reliability of the contents to users' judgment.
Japanese partner needed to record/release radioprotective drug
<< DESCRIPTION >>
Novosibirsk innovative company on the basis of biologically active substances of natural origin developed immunostimulating drug, radioprotection and adaptogenic effect.
The main active principle of the drug is a natural mixture of proteins and cytokines a number of ribonucleic acids with different structures, including information and double-stranded form, are in balanced concentrations.
In laboratory tests of the drug were modeled factors known to cause not only immunological failure, but also negatively affect all systems and organs.
Shown that the introduction of the drug speeds up the excretion of the organism of experimental animals isotopes of heavy metals, such as strontium.
The most interesting results were obtained in experimental animals exposed to X-rays in a sublethal dose. The introduction of the drug in this case allowed to recover significantly immunoreactivity of irradiated animals. It was shown that the drug has the effect of radiotherapy in relation to stem cells of the immune system. A similar effect was obtained in T-cell immunodeficiency caused by prior administration of hydrocortisone.
Thus, developed on the basis of biologically active substances of natural origin drug has a pronounced immunostimulant, adaptogenic and radioprotective action, which makes it promising to reduce risk while in the areas of environmental and technological disasters, including areas with high radiation.
Our company seeks Japanese partners to record and release the drug in the pharmaceutical market in Japan.
Please contact us if you take an interest in.